-
Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute WorkshopP Greenland, ED Michos, N Redmond et al. -
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesWanner C, Inzucchi SE, EMPA-REG OUTCOME Investigators.
-
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER TrialMurphy SA, Pedersen TR, Gaciong ZA et al.
-
High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized StudyJ Henzel, C Kępka, M Kruk et al.
-
Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetesCostacou T, Ferrell RE, Orchard TJ.
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyPerkovic V, Jardine MJ, CREDENCE Trial Investigators.
-
Association Between Depressive Symptoms and Incident Cardiovascular DiseasesEL Harshfield, L Pennells, Emerging Risk Factors Collaboration.
-
The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesisHI Chen , B Sharma, K Red-Horse et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
